非小细胞肺癌分子亚型中循环肿瘤细胞特征的前瞻性检查
本研究前瞻性纳入125例初治IIIb-IV期非小细胞肺癌患者,用CellSearch分析循环肿瘤细胞(CTC)并加抗波形蛋白抗体评估间质特征。基线时40.8%患者总CTC阳性,20.8%波形蛋白阳性CTC阳性;总CTC≥5个与总生存期缩短相关,EGFR突变亚组波形蛋白阳性CTC增多,KRAS突变腺癌未见波形蛋白阳性CTC。
要点
- 基线总CTC≥5个的晚期NSCLC患者总生存期显著缩短(HR 0.55,95%CI 0.33-0.92,P=0.022)。
- EGFR突变亚组波形蛋白阳性CTC增多(N=21/94,均值1.24 vs 1.22,P=0.013)。
- KRAS突变腺癌中波形蛋白阳性CTC完全缺失(N=19/78,均值0 vs 1.4,P=0.006)。
核心结论
- 基线总CTC≥5个的晚期非小细胞肺癌患者预后不良,EGFR突变患者的CTC表达上皮-间质转化特征,KRAS突变腺癌患者未见此特征。
研究设计与样本
- 前瞻性研究纳入125例初治IIIb-IV期非小细胞肺癌患者,行CellSearch分析,并加抗波形蛋白抗体检测CTC间质特征。
主要发现
- 基线时51/125例(40.8%)总CTC阳性,26/125例(20.8%)波形蛋白阳性CTC阳性。
- 多因素分析显示总CTC≥5个患者较<5个患者总生存期显著缩短(HR 0.55,95%CI 0.33-0.92,P=0.022),无进展生存期无显著差异(HR 0.68,95%CI 0.42-1.1,P=0.118)。
- 波形蛋白阳性与阴性CTC患者总生存期无显著差异(HR 1.24,95%CI 0.67-2.28,P=0.494)。
- EGFR突变亚组波形蛋白阳性CTC增多(N=21/94,均值1.24 vs 1.22,P=0.013)。
- ALK重排亚组总CTC减少(N=13/90,均值1.69 vs 5.82,P=0.029),KRAS突变腺癌波形蛋白阳性CTC完全缺失(N=19/78,均值0 vs 1.4,P=0.006)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We report the first study examining the clinical, numerical and biological properties of circulating tumor cells according to molecular subtypes of non-small-cell lung cancer. PATIENTS AND METHODS: 125 patients with treatment-naïve stage IIIb-IV NSCLC were prospectively recruited for CellSearch analysis. Anti-vimentin antibody was included for examination of CTCs to assess their mesenchymal character. Associations of total CTCs and vimentin-positive (vim +) CTCs with clinical characteristics, tumor genotype, and survival were assessed. RESULTS: 51/125 patients (40.8%) were total CTC+ and 26/125 (20.8%) were vim CTC+ at baseline. Multivariate analysis showed patients with ≥5 total CTCs had significantly reduced OS (HR 0.55, 95% CI 0.33-0.92, P = 0.022) but not PFS (HR 0.68, 95% CI 0.42-1.1, P = 0.118) compared to patients with <5 total CTCs. No OS difference was evident between vim+ CTC and vim-negative CTC patients overall (HR 1.24, 95% CI 0.67-2.28, P = 0.494), but after subdivision according to NSCLC driver mutation, we found an increase of vim+ CTCs in the EGFR-mutated subgroup (N = 21/94 patients; mean 1.24 vs 1.22 vim+ CTCs, P = 0.013), a reduction of total CTCs in the ALK-rearranged subgroup (N = 13/90 patients; mean 1.69 vs 5.82 total CTCs, P = 0.029), and a total absence of vim+ CTCs in KRAS-mutated adenocarcinomas (N = 19/78 patients; mean 0 vs 1.4 vim+ CTCs, P = 0.006). CONCLUSIONS: We validate that the baseline presence of ≥5 total CTCs in advanced NSCLC confers a poor prognosis. CTCs from EGFR-mutant NSCLC express epithelial-mesenchymal transition characteristics, not seen in CTCs from patients with KRAS-mutant adenocarcinoma.
引用
- Lindsay CR, Faugeroux V, Michiels S, et al. A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups. Ann Oncol. 2017. PMID: 28633480. doi:10.1093/annonc/mdx156
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。